Sources
[1] Pottecher J, Sato VAH, Plétan Y, et al. A Novel Anti-Thrombotic, Glenzocimab, inCovid-19 acute respiratory distress syndrome (Cov-ARDS). In: 02.01 - Acutecritical care. European Respiratory Society, 2022: 2878.
In November 2022, Acticor Biotech announced the partnership with the University of Birmingham and announced the first clinical trial to test new drug glenzocimab for myocardial infarctions.
With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. This randomized, double-blind Phase 2b LIBERATE study will recruit more than 200 patients to test the tolerance and the efficacy of glenzocimab 1000 mg, versus placebo, to reduce heart damage following a myocardial infarction (MI), commonly known as a heart attack.
The trial will be run at the University of Birmingham with expert clinicians from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. Bringing together experience in running multi-site clinical trials from the Clinical Trial Units (CTU) and expertise in heart diseases, the team will see whether glenzocimab will reduce the amount of dead heart tissue in patients following an ST segment elevation myocardial infarction (STEMI), the most serious type of heart attack.
In response to the global COVID-19 pandemic, Acticor Biotech proposed using glenzocimab to treat acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients, in the context of a phase 2 clinical study (GARDEN NCT04659109).
The scientific rationale was to limit the contribution of platelets to uncontrolled pulmonary inflammation and prevent the secondary effect of a pro-thrombotic environment without inducing bleeding.
In February 2022, Acticor Biotech announced results of this exploratory study conducted in France and in Brazil between December 2020 and June 2021, in a total of 62 randomized patients (30 to glenzocimab and 32 to placebo):
- The safety data analysis confirmed the good tolerability of glenzocimab administered at a daily dose of 1000 mg for three consecutive days, despite concomitant treatment with heparins in all patients.
- No difference was shown for the primary efficacy endpoint of progression from moderate to severe respiratory distress between glenzocimab and the placebo, both administered in conjunction with the standard of care.
GARDEN results were presented by Pr Julien Pottecher, Coordinating Investigator of GARDEN Study, at the European Respiratory Society Congress 20221 (link to press release).
In collaboration with SATT OUEST VALORISATION, Brest University Hospital, Université de Bretagne Occidentale, INSERM and EFS, Acticor Biotech is developing the early genomic profiling of stroke in order to design an emergency point-of-care device that will enable the rapid diagnosis of acute ischemic stroke and initiation of its treatment without additional imaging delays.
[1] Pottecher J, Sato VAH, Plétan Y, et al. A Novel Anti-Thrombotic, Glenzocimab, inCovid-19 acute respiratory distress syndrome (Cov-ARDS). In: 02.01 - Acutecritical care. European Respiratory Society, 2022: 2878.